Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 2 天前评分90
正文 · 机器翻译
TALENT—新辅助 TDXd（6-8 个周期）+/- AI，用于 HER2 低表达、HR+ 早期乳腺癌
ypCR // RCB
TDXd 7% // 16%
T-DXd/AI: 3% // 9%
T-DXd→ TC: 17% // 17%
作者认为获益“有限”；我会说是“令人失望”。在 ER+ 疾病中，ypCR 并不是同等终点 #ESMO26 @OncoAlert
564 浏览 · 17 赞 · 8 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Stephanie Graff, MD, FACP, FASCO · x.com